<DOC>
	<DOCNO>NCT01449617</DOCNO>
	<brief_summary>A carotid stenosis treat invasive procedure revascularization lumen reduce 70 % lumen reduce 50 % patient symptoms attributable affected carotid district last 6 month . Two option treatment patient carotid stenosis exist currently : traditional surgical intervention removal plaque carotid endoarterectomy ( CEA ) percutaneous transluminal carotid angioplasty balloon associate position stent catheter bring directly carotid artery ( CAS ) . The main complication procedure early thrombosis , phenomenon platelet play central role . The importance effective inhibition platelet activation patient widely demonstrate . Clinical study patient undergo PTCA demonstrate optimal treatment prevention stent thrombosis dual antiplatelet regimen aspirin plus clopidogrel , compare single drug . Given specific clinical trial assess best antiplatelet therapeutic regimen CAS stenting , extension finding ischemic heart disease CAS patient treat aspirin plus clopidogrel . Several study demonstrate elevated residual platelet reactivity despite treatment clopidogrel associate increase risk major adverse cardiovascular event ( MACE ) stenting coronary disease . No data instead available possible predictive value residual platelet reactivity incidence ischemic cardiovascular event patient atherosclerotic carotid disease undergo CAS stenting . Aim study assess predictive value residual platelet reactivity , measure different laboratory test patient undergo CAS stenting treat aspirin plus clopidogrel , incidence cardiovascular complication ( major adverse ischemic event ) .</brief_summary>
	<brief_title>Residual Platelet Reactivity Patients Antiplatelet Therapy After Carotid Angioplasty With Stenting</brief_title>
	<detailed_description>STUDY DESIGN The study enroll 110 patient undergo stenting critical carotid stenosis , either symptomatic ( previous event cerebral ischemia ) asymptomatic , undergo CAS . All patient undergo CAS Center fit predefined Criteria enrol study . Dual-antiplatelet treatment aspirin clopidogrel administer patient modality use coronary heart disease patient undergoing PTCA . Implanted stent CAS patient bare metal stent ( BMS ) therefore , analogy study ACS , duration dual-antiplatelet treatment one month ; later patient continue indefinitely aspirin . Clopidogrel , start 48 hour procedure load dose 300mg continue 75mg/day ; aspirin give dose 100-325mg/day . Platelet reactivity assessment carried-out : - intervention , - 1 week treatment , - 1 month treatment - 1 year . All patient recall clinical examination 1 6 month 1 year .</detailed_description>
	<mesh_term>Carotid Artery Diseases</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Inclusion criterion Informed write consent No contraindication dualantiplatelet treatment Exclusion criterion Age &lt; 18 &gt; 80 year old Use oral anticoagulant Use dipyridamole , cilostazol , NSAIDs Myeloproliferative syndrome paraproteinemia Liver kidney failure Thrombocytopathies Platelets count &lt; 100000 &gt; 450000/Âµl Haemoglobin &lt; 8g/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Carotid stenosis</keyword>
	<keyword>Aspirin plus Clopidogrel</keyword>
	<keyword>Residual platelet reactivity</keyword>
</DOC>